Literature DB >> 15820421

Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain.

Francesco Angelucci1, Luigi Aloe, Angela Iannitelli, Susanne H M Gruber, Aleksander A Mathé.   

Abstract

Nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) are proteins involved in neuronal survival, neurite outgrowth and synapse formation. Recent observations suggest that treatment with typical and atypical antipsychotic drugs affect NGF and BDNF levels in the rat brain. The atypical antipsychotic olanzapine has a low incidence of side effects, such as extrapyramidal and anticholinergic symptoms. Since NGF and BDNF are involved in the regulation of cholinergic, dopaminergic and serotonergic neurons in the central nervous system (CNS) we hypothesized that chronic olanzapine treatment will influence the distribution of NGF and BDNF in the rat brain. To test this hypothesis we administered olanzapine for 29 days in the drinking water at the doses of 3 and 15 mg/kg body weight and measured the levels of NGF and BDNF in the brain of Wistar rats. Olanzapine increased NGF in the hippocampus, occipital cortex and hypothalamus. In contrast, olanzapine decreased BDNF in the hippocampus and frontal cortex. Although the significance of these findings is not clear, a heuristic hypothesis is that olanzapine's clinical effects and a favorable side effect profile are in part mediated by neurotrophins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15820421     DOI: 10.1016/j.euroneuro.2004.11.005

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  18 in total

1.  Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia.

Authors:  Philip R Szeszko; Katherine L Narr; Owen R Phillips; Joanne McCormack; Serge Sevy; Handan Gunduz-Bruce; John M Kane; Robert M Bilder; Delbert G Robinson
Journal:  Schizophr Bull       Date:  2010-11-17       Impact factor: 9.306

2.  Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment.

Authors:  Ashley Tsai; Ying-Jay Liou; Chen-Jee Hong; Chia-Liang Wu; Shih-Jen Tsai; Ya Mei Bai
Journal:  Neuromolecular Med       Date:  2011-09-29       Impact factor: 3.843

Review 3.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

4.  Brain differences in first-episode schizophrenia treated with quetiapine: a deformation-based morphometric study.

Authors:  Chunlan Yang; Shuicai Wu; Wangsheng Lu; Yanping Bai; Hongjian Gao
Journal:  Psychopharmacology (Berl)       Date:  2014-08-02       Impact factor: 4.530

Review 5.  Research in people with psychosis risk syndrome: a review of the current evidence and future directions.

Authors:  Christoph U Correll; Marta Hauser; Andrea M Auther; Barbara A Cornblatt
Journal:  J Child Psychol Psychiatry       Date:  2010-02-26       Impact factor: 8.982

6.  Aberrant Hippocampal Connectivity in Unmedicated Patients With Schizophrenia and Effects of Antipsychotic Medication: A Longitudinal Resting State Functional MRI Study.

Authors:  Nina Vanessa Kraguljac; David Matthew White; Nathan Hadley; Jennifer Ann Hadley; Lawrence Ver Hoef; Ebony Davis; Adrienne Carol Lahti
Journal:  Schizophr Bull       Date:  2016-02-12       Impact factor: 9.306

Review 7.  BDNF-TrkB signaling and neuroprotection in schizophrenia.

Authors:  Chirayu D Pandya; Ammar Kutiyanawalla; Anilkumar Pillai
Journal:  Asian J Psychiatr       Date:  2012-11-03

8.  Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo.

Authors:  Tobias Gyárfás; Juha Knuuttila; Päivi Lindholm; Tomi Rantamäki; Eero Castrén
Journal:  Cell Mol Neurobiol       Date:  2009-09-24       Impact factor: 5.046

9.  Asenapine sensitization from adolescence to adulthood and its potential molecular basis.

Authors:  Qing Shu; Rongyin Qin; Yingzhu Chen; Gang Hu; Ming Li
Journal:  Behav Brain Res       Date:  2014-08-02       Impact factor: 3.332

10.  Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia.

Authors:  Ripu D Jindal; Anil K Pillai; Sahebrao P Mahadik; Kevin Eklund; Debra M Montrose; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2010-01-21       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.